Alan Robin is an Ophthalmology physician. OpenAlex indexes 376 publications with 22,292 citations (h-index 57); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6115 Falls Rd
Suite 333
Baltimore, MD 212092219
Telephone
410-377-2422Registry record last updated 29 Jan 2019.
Clinical trials
- Observational Study of How Patients Take Eye Drops
Sponsor: Robin, Alan L., M.D.
- Impact of Health Literacy and Other Factors on Glaucoma Patient Adherence in South India
Sponsor: Robin, Alan L., M.D.
- Eye Drop Use in Glaucoma Patients Through Patient Surveys and Video Observations
Sponsor: Robin, Alan L., M.D.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Glaukos CorporationProgram year20231 payment
- Alcon Vision LLCProgram year20231 payment
- NEW WORLD MEDICAL,INC.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
81.7%Prostaglandin Analog40.7%Latanoprost63%Travatan Z20%Lumigan17%Part D≥65 patientsCarbonic Anhydrase Inhibitor20.4%Dorzolamide-Timolol54%Dorzolamide Hcl17%Azopt17%Simbrinza11%Part D<11 patients+ 3 more classes in this area
Cardiovascular
13.3%Beta blocker13.3%Timolol Maleate100%Part D≥33 patientsNervous system
5%Cholinergic Receptor Agonist5%Pilocarpine Hcl100%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The relationship between intraocular pressure and glaucoma: An evolving concept
Progress in Retinal and Eye Research
2024 - Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial
American Journal of Ophthalmology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Richard Spaide, MD
Vitreous Retina Macula Consultants of New York
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”